Polypeptide With Localisation/Targeting Motif TRIZ Cases
- Amyelois Transposase Vectors for Stable Eukaryotic DNA Integration
An Amyelois piggyBac-like transposase boosts excision and transposition while reducing host inactivation for stable heterologous DNA expression.
- Multi-Antigen WNT Cancer Vaccine for Checkpoint Resistance
A multi-antigen nucleic acid vaccine targets WNT-pathway neoantigens to boost CD8+ T cell response and improve checkpoint-resistant cancer treatment.
- Mutant RAS T-Cell Receptors for HLA-Specific Cancer Targeting
Engineered T-cell receptors bind mutant RAS peptides on HLA-C*08:02 to trigger selective tumor cell killing when inhibitors fall short.
- CAR-NK Signaling Design for Solid Tumor Killing
Novel CARs using DAP10 or DAP12 with SAP or EAT2 help NK cells overcome inhibitory signaling and improve solid tumor killing with better safety.
- Chimeric Transposases for Shorter ITR Site-Specific Integration
By fusing PiggyBac catalytic activity with MosI DNA binding, this case enables precise TTAA integration with shorter ITRs and fewer transposase molecules.
- Plant Organelle Base Editing With Split Deaminase Composition
A split deaminase composition enables A-to-G and C-to-T editing in plant organelle DNA, overcoming guide RNA delivery limits.
- PD-1 IL-2 Immunoconjugates for Selective T Cell Activation
Mutant IL-2 linked to a PD-1 antibody shifts activation toward cytotoxic T cells, reducing Treg-driven immunosuppression and toxicity.
- Modular CAR Signaling With Small-Molecule Shutdown Control
A small molecule disrupts receptor-signaling heterodimerization, giving CAR cells reversible potency control to limit toxic effects.
- Dynamin 1 Peptide Therapy for Tau-Driven Synaptic Dysfunction
A dynamin 1-derived peptide blocks tau-driven microtubule over-assembly, preserves vesicle endocytosis, and restores synaptic transmission.
- Citrullinated Antigen CAR-Treg Therapy for Targeted HS Lesions
Engineered CAR-Treg cells bind citrullinated proteins in HS lesions to improve local immune control without broad corticosteroid suppression.
- Chimeric RSV F in B/HPIV3 Vectors for Stronger Vaccine Immunity
A chimeric RSV F linked to PIV3 membrane domains improves viral incorporation and induces stronger neutralizing immunity in recombinant vaccine vectors.
- CAR-T Cell Preparation Without CD28 for Faster Expansion
A CD3/TCR agonist with IL-7 and IL-21 replaces CD28 stimulation to shorten CAR-T preparation to 1-4 days while reducing cost and differentiation.
- Dual-Target CAR-T Cells to Prevent CD19 Antigen Escape
Dual CD19/CD20 recognition helps CAR-T cells overcome antigen escape and improve tumor killing in relapsed B-cell treatment.
- Chimeric Engulfment Receptors for Targeted Phagocytic Inflammation
A modular receptor links target-cell binding with engulfment signaling to boost phagocytosis and inflammatory clearance of diseased cells.
- DLL3-Targeting Antibodies for Selective Neuroendocrine Cell Killing
High-specificity DLL3 antibodies enable CAR-T and CAR-NK targeting of neuroendocrine tumors while limiting cross-reactivity and side effects.
- Cell-Penetrating Peptide Fragment for Efficient Cargo Transfer
A short RRRRSNRRG peptide improves cell membrane permeability and boosts transfer of nucleic acids, polypeptides, and drugs into eukaryotic cells.
- Stabilized IL-18 Variants That Resist IL-18BP Inhibition
Targeted IL-18 mutations reduce IL-18BP binding while preserving receptor signaling, improving immune activation and anti-tumor activity.
- Glycosylated Cell-Penetrating Peptides for Blood-Brain Barrier Delivery
Directly glycosylated arginine-rich peptides improve blood-brain barrier delivery of therapeutic SSOs while lowering dose and toxicity.
- FAP-Binding Chimeric Proteins for CAF Polarization in Tumors
Modular FAP-binding chimeric proteins reprogram CAFs, enhance antigen presentation, and localize therapy within tumors.
- Cas9-FokI Fusion Proteins for High-Specificity Genome Editing
Split Cas9 cleavage and FokI dimerization reduce off-target DNA cutting while enabling precise genome editing and recombination.
- Cell-Permeant Polypeptides for Endothelial Dysfunction Repair
Chimeric cell-permeant polypeptides restore endothelial function by reducing p38 MAPK phosphorylation and improving vascular relaxation.
- Anti-MUC1* Antibodies for Selective Solid Tumor Targeting
Antibodies targeting the MUC1* PSMGFR region improve solid tumor cell killing while reducing off-tumor toxicity in CAR, BiTE, and ADC use.
- Autophagy-Suppressed CAR-T Cells for Solid Tumor Persistence
CRISPR suppression of autophagy genes in CAR-T lymphocytes improves persistence and anti-tumor activity in glucose-competitive solid tumors.
- Modified Conantokin Peptides for Selective Extrasynaptic GluN2B Inhibition
Modified Conus-derived peptides selectively inhibit extrasynaptic GluN2B receptors to reduce neuronal apoptosis while preserving synaptic function.
- Synthetic MVA Coronavirus Vaccine Platform for Vector Availability
Synthetic MVA DNA fragments replace restricted vector stocks while preserving strong coronavirus antigen expression and long-term immunity.
- TIS and Signal Peptide Sequence for Predictable Protein Expression
A novel TISEVO translation initiation sequence boosts mammalian recombinant protein yield while preserving protein quality and expression predictability.
- Dual-Target CAR/TCR Binding Motifs Against CD19 and CD20 Evasion
Dual CD19/CD20 binding motifs help engineered T cells overcome tumor evasion and improve lymphoma and leukemia cell killing.
- CAR T-Cell Receptor Architecture for Broader Tumor Antigen Targeting
Engineered CAR immune cells use interchangeable receptor domains to expand tumor antigen targeting while preserving signaling and cancer cell killing.
- Bispecific CD20-BCMA CAR-T Cells for Durable B Cell Depletion
Engineered CAR-T cells that bind CD20 and BCMA improve B cell depletion and support longer remission in autoimmune disease and cancer.
- Anti-DLL3 CAR-T Receptors for Targeted Small-Cell Lung Cancer
Engineered anti-DLL3 CAR-T receptors use scFv or sdAb binding and co-stimulatory signaling to selectively destroy DLL3-expressing SCLC cells.
- Fusosome Membrane Protein Delivery Without Viral Vectors
Fusosomes use fusogen-equipped lipid bilayers to deliver membrane proteins to target cells with higher specificity while avoiding viral genetic contamination.
- Muscle-Specific Expression Cassettes for Dystrophin Gene Editing
Muscle-specific promoters and regulatory elements focus nuclease expression in skeletal and cardiac tissue to restore dystrophin in DMD.
- Programmable RNA Methylation Editors for Precise Epigenetic Targeting
Guide RNA-directed fusion proteins add or remove RNA methyl groups with limited off-target editing, enabling precise epigenetic control.
- Anti-Aβ Monoclonal Antibodies for Plaque Clearance
Monoclonal anti-Aβ antibodies use optimized variable regions to bind toxic soluble and fibrillar Aβ, improving plaque clearance and neutralization.
- Novel Cas Protein Variants for Flexible PAM Gene Editing
Novel Cas protein variants expand PAM recognition and improve eukaryotic expression, enabling more precise and adaptable gene editing.
- Split Luciferase Polypeptide Kit for Low-Hindrance Interaction Detection
Small complementary luciferase polypeptides detect intermolecular interactions with high sensitivity while minimizing steric hindrance and expression issues.
- Engineered T Cell Composition With Optimized CD4/CD8 Pooling
Pooling enriched CD4+ and CD8+ T cells at an optimized ratio in serum-free media improves transduction success, viability, and expansion.
- Nme2Cas9-Deaminase Base Editing for Broader PAM Targeting
Using Nme2Cas9 fused to a deaminase expands PAM-compatible editing sites and improves single-base precision with fewer off-target effects.
- EGFRvIII-Binding CARs and Antibodies With Reduced Off-Tumor Toxicity
Engineered EGFRvIII binders improve solid-tumor immune targeting while minimizing wild-type EGFR binding and off-tumor toxicity.
- Teleost Invariant Chain Fragments for Multi-Antigen Cancer Vaccines
Short teleost invariant chain MPD fragments boost T-cell responses to multiple cancer antigens while fitting vector size limits.
- Bispecific CAR T-Cell Factories for Selective ccRCC Targeting
Engineered CAR T-cells target CAIX and CD70 while locally secreting checkpoint antibodies to improve solid tumor killing and limit off-tumor effects.
- Mutant AID Base Editor for Higher-Efficiency Single-Base Mutation
A mutant AID editor cuts molecular weight while boosting targeted single-base mutation efficiency and reducing off-target DNA editing.
- Fratricide-Resistant CAR Immune Cells via CD2 Base Editing
Base editing inactivates endogenous CD2 to prevent CAR immune cell fratricide while preserving genomic stability and anti-neoplasia activity.
- Recombinant Silk Fiber Composition for Microfiber-Scale Production
Engineered block copolymer silk proteins enable scalable microbial production of strong, flexible fibers in microfiber diameters.
- HBG1/HBG2 Gene-Targeting Composition for Safer Fetal Hemoglobin Induction
Guide RNAs with dCas9 fusion proteins target HBG1/HBG2 and BCL11A to raise fetal hemoglobin with improved safety for hemoglobinopathies.
- hPSC-Derived Universal NK Cells With CAR Targeting and Memory Persistence
Engineered hPSC-derived NK cells use ID2, NFIL3, SPI1 and CAR knock-ins to improve tumor killing, persistence, and reproducible production.
- CLL-1 CAR-T Therapy for Smoldering Neuroinflammation in MS
CLL-1-directed CAR-T cells deplete pathogenic macrophages in MS, targeting smoldering neuroinflammation beyond T- and B-cell therapies.
- Engineered Cascade Complexes With Cas8-FokI Fusion for Eukaryotic Editing
Cas8-FokI fusion proteins and modified guides simplify Type I Cascade expression in eukaryotic cells while improving DNA targeting and cleavage.
- HLA-G Isoform-Specific CARs for Tumor Immunosuppression
CARs tuned to β2M-associated and β2M-free HLA-G isoforms help eliminate immunosuppressive tumor cells and improve solid tumor targeting.
- Double-Immobilized Yeast Catalyst for Low-Cost Rebaudioside Synthesis
Surface-displayed yeast enzymes with in-situ UDPG regeneration cut rebaudioside synthesis cost while improving reuse and conversion.